CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...
That’s just one of the reasons that National Blood Donor Month, which has taken place each Jan...
CTS communications distributed on July 6th and July 20th.In working with Grifols on the availability...
As a reminder, CTS will be exhibiting this weekend at the AABB Annual Meeting in San Antonio, T...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
As winter weather continues to move through parts of the US, we would like to remind you it may be n...